Back to top
more

Amarin (AMRN)

(Real Time Quote from BATS)

$0.88 USD

0.88
198,553

0.00 (0.34%)

Updated Apr 30, 2024 10:57 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amarin Loses Patent Appeal in Vascepa Lawsuit, Stock Dips

by Zacks Equity Research

Amarin (AMRN) receives a setback as the U.S. Court of Appeals upholds a ruling by Nevada district court in favor of the generic companies related to patent litigation against Vascepa.

Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Amarin (AMRN) in Focus: Stock Moves 5.5% Higher

by Zacks Equity Research

Amarin (AMRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe

by Zacks Equity Research

Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results

Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

Amneal (AMRX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) will provide financial updates when it reports second-quarter 2020 results.

Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amarin (AMRN) closed at $7.03, marking a +1.59% move from the previous day.

Implied Volatility Surging for Amarin (AMRN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Amarin (AMRN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Amarin (AMRN) closed at $6.92, marking a +0.58% move from the previous day.

Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Amarin (AMRN) closed at $6.78 in the latest trading session, marking a +0.89% move from the prior day.

Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Amarin (AMRN) closed the most recent trading day at $6.59, moving -1.35% from the previous trading session.

Why Amarin (AMRN) Stock Might be a Great Pick

by Zacks Equity Research

Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amarin (AMRN) closed at $6.68, marking a -1.18% move from the previous day.

Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports wider-than-expected first-quarter 2020 loss.

Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil

by Zacks Equity Research

Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.

Amarin's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Amarin.

Amarin's (AMRN) Q1 Loss In Line With Estimates, Sales Beat

by Zacks Equity Research

Amarin's (AMRN) strong revenue growth in the first quarter is attributable to continued solid demand for its cardiovascular drug, Vascepa.

Amarin (AMRN) Meets Earnings Estimates in Q1, Revenues Tops

by Zacks Equity Research

Amarin's (AMRN) first quarter earnings were in line with expectations. However, sales beats estimates. Stock down.

Is a Beat in Store for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research

Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More

by Zacks Equity Research

Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.

Is Amarin (AMRN) Stock a Solid Choice Right Now?

by Zacks Equity Research

Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Amarin's Stock Plunges Following Unfavorable Patent Ruling

by Zacks Equity Research

Amarin (AMRN) plans to appeal against unfavorable ruling from the District of Nevada in a patent litigation related to Vascepa and file an injunction against generic companies.

Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.